Loading data for TSHA — first visit, this takes a few seconds.

Alerta

Taysha Gene Therapies Inc... (TSHA)

NasdaqGS: TSHA · Precio en tiempo real · USD

6.43

+0.24 (3.88%)

Al cierre: Aug 19, 2026, 8:00 PM

6.42

-0.16%

Fuera de horario: 5:44 PM

3.88% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	2.1B
Ingresos (TTM)	5.49M
Beneficio neto (TTM)	-149.63M
Beta	1.19
EPS (TTM)	-0.41
Ratio PER (TTM)	n/a
Adelante PE	-13.47
P/B (TTM)	8.71
P/S (TTM)	381.97
Earnings Date	Nov 4, 2026

Precio de venta	n/a
Volumen	2,389,406
Volumen medio (20D)	3,096,825
Abierto	6.40
Anterior Cerrar	6.19
Rango del día	6.29 - 6.52
Rango de 52 semanas	2.71 - 7.30
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de TSHA

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Sep 24, 2020

Empleados 99

Bolsa de Valores NasdaqGS

Símbolo bursátil TSHA

Sitio web https://www.tayshagtx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Taysha Gene Therapies fueron 9.77M, un aumento de 17.28% en comparación con 8.33M del año anterior. Las ganancias fueron -109M, un aumento de 22.06%.

Estados financieros

Sorpresa de resultados

Taysha Gene Therapies ha publicado sus resultados trimestrales en Aug 11, 2026:

Ingresos de $0 falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de -0.13 falla las estimaciones por -0.02, con -62.50% Disminución interanual.

Próxima publicación de resultados

Está previsto que Taysha Gene Therapies Inc. publique sus resultados el Nov 4, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

6 días hace · Simply Wall St.

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and ...

1 semana hace · Moby

Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary

Moby summary of Taysha Gene Therapies, Inc.'s Q2 2026 earnings call

1 semana hace · GuruFocus.com

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

Company reports 100% response rate in Part A trial, completes pivotal dosing, and maintains $455.4 million cash position into 2028

1 semana hace · MarketBeat

Taysha Gene Therapies Q2 Earnings Call Highlights

Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential bi...

1 mes hace · Insider Monkey

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now. On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten publ...

Página 1 de 2

Taysha Gene Therapies Inc... (TSHA)